Draft Guidance Proposes Longer Stability Testing for Generics

Published Online: Friday, December 14, 2012
Follow Pharmacy_Times:
A draft guidance on abbreviated new drug application (ANDA) stability testing could require 6 months of testing rather than the 3 currently required. The draft guidance is available through the FDA website, and is open to written and electronic comments.

In addition, the current standards date from 1995 and allow stability studies to be conducted based on long-term room temperatures. This guideline is no longer adequate to determine the stability of new drug compounds, the FDA stated.

Instead, the draft recommendations suggest following the International Conference on Harmonization guidances Q1A through Q1F, which pertain to new drug approvals. If accepted, the guidance would require generic manufacturers to submit data from 3 pilot drug batches or 2 pilot drug batches and a small-scale drug batch. At the time of submission, companies should provide 6 months of accelerated and long-term condition data, as well as submitting multiple lots of drug components.

In addition, the draft guidance would require manufacturers to submit a fully packaged exhibit batch, use 3 drug batches when analyzing for manufacturing variability, and provide a statistical analysis of the data, where appropriate.

Related Articles
The FDA is seeking comments on 28 new and 15 revised recommendations providing product-specific guidance on the design of bioequivalence studies to support Abbreviated New Drug Applications (ANDAs).
Mylan Inc. today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., in connection with the filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Sorafenib Tablets, 200 mg. This product is the generic version of NEXAVAR®, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$